Design Therapeutics Inc (DSGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Design Therapeutics Inc (DSGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.16 Million) by net assets ($199.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Design Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Design Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Design Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Design Therapeutics Inc ranked by their cash flow conversion efficiency. See Design Therapeutics Inc debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Better Home & Finance Holding Company
NYSE:BETR
|
-0.797x |
|
Tianjin Jinbin Development
SHE:000897
|
0.007x |
|
Shenmao Technology Inc
TW:3305
|
-0.048x |
|
Yingkou Fengguang Advanced Material Co.Ltd.
SHE:301100
|
N/A |
|
Nantex Industry Co Ltd
TW:2108
|
0.002x |
|
Zhejiang HISUN Biomaterials Co. Ltd. A
SHG:688203
|
N/A |
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
0.022x |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
0.043x |
Annual Cash Flow Conversion Efficiency for Design Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Design Therapeutics Inc from 2019 to 2024. View DSGN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $242.10 Million | $-43.10 Million | -0.178x | +15.57% |
| 2023-12-31 | $277.69 Million | $-58.56 Million | -0.211x | -34.51% |
| 2022-12-31 | $327.31 Million | $-51.32 Million | -0.157x | -103.94% |
| 2021-12-31 | $382.13 Million | $-29.38 Million | -0.077x | -110.03% |
| 2020-12-31 | $-11.31 Million | $-8.67 Million | 0.766x | +1907.43% |
| 2019-12-31 | $-3.64 Million | $-139.00K | 0.038x | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more